A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma.
Hamilton AK, Radaoui AB, Tsang M, Martinez D, Conkrite KL, Patel K, Sidoli S, Delaidelli A, Modi A, Rokita JL, Lane MV, Hartnett N, Lopez RD, Zhang B, Zhong C, Ennis B, Miller DP, Brown MA, Rathi KS, Raman P, Pogoriler J, Bhatti T, Pawel B, Glisovic-Aplenc T, Teicher B, Erickson SW, Earley EJ, Bosse KR, Sorensen PH, Krytska K, Mosse YP, Havenith KE, Zammarchi F, van Berkel PH, Smith MA, Garcia BA, Maris JM, Diskin SJ.
Hamilton AK, et al. Among authors: brown ma.
Cancer Cell. 2024 Nov 11;42(11):1970-1982.e7. doi: 10.1016/j.ccell.2024.10.003. Epub 2024 Oct 24.
Cancer Cell. 2024.
PMID: 39454577
Free article.